Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland (Jan, 10.1080/03009742.2022.2151109, 2023)

In Finnish clinical practice, apremilast is mainly used between conventional synthetic therapy and biologics, with at least as high treatment persistence as reported in previous studies. Apremilast users were older with higher comorbidity burden than biologics users.